

Highlights of This Issue 2155

REVIEW

- 2157 **A Review of Trabectedin (ET-743):
A Unique Mechanism of Action**
Maurizio D'Incalci and Carlos M. Galmarini

THERAPEUTIC DISCOVERY

- 2164 **Lipoxin A₄ and Its Analogue
Suppress the Tumor Growth of
Transplanted H22 in Mice:
The Role of Antiangiogenesis**
Ying Chen, Hua Hao, Songqing He,
Lei Cai, Yongsheng Li, Shunze Hu,
Duyun Ye, John Hoidal, Ping Wu,
and Xiaoping Chen
- 2175 **Decreased Survival of Human
Breast Cancer Cells Expressing
HER2/*neu* on *In vitro* Incubation
with an Anti-HER2/*neu* Antibody
Fused to C5a or C5a_{desArg}**
Jaheli Fuenmayor, Karin Perez-Vazquez,
Daniel Perez-Witzke, Manuel L. Penichet,
and Ramon F. Montano
- 2186 **Systematic Interpretation of
Comutated Genes in Large-Scale
Cancer Mutation Profiles**
Yunyan Gu, Da Yang, Jinfeng Zou,
Wencai Ma, Ruihong Wu, Wenyuan Zhao,
Yuannv Zhang, Hui Xiao, Xue Gong,
Min Zhang, Jing Zhu, and Zheng Guo
- 2196 **γ -Tocotrienol Promotes
TRAIL-Induced Apoptosis through
Reactive Oxygen Species/
Extracellular Signal-Regulated
Kinase/p53-Mediated
Upregulation of Death Receptors**
Ramaswamy Kannappan,
Jayaraj Ravindran, Sahdeo Prasad,
Bokyung Sung, Vivek R. Yadav,
Simone Reuter, Madan M. Chaturvedi,
and Bharat B. Aggarwal
- 2208 **Galectin-3 Promotes Chronic
Activation of K-Ras and
Differentiation Block in Malignant
Thyroid Carcinomas**
Ran Levy, Meital Grafi-Cohen,
Zaki Kraiem, and Yoel Kloog

- 2220 **Sorafenib Activates CD95 and
Promotes Autophagy and Cell
Death via Src Family Kinases in
Gastrointestinal Tumor Cells**
Margaret A. Park, Roland Reinehr,
Dieter Häussinger,
Christina Voelkel-Johnson,
Besim Ogretmen, Adly Yacoub,
Steven Grant, and Paul Dent

- 2232 **Heat Shock Protein 90 Inhibition
Depletes TrkA Levels and Signaling
in Human Acute Leukemia Cells**
Rekha Rao, Srilatha Nalluri, Warren Fiskus,
Ramesh Balusu, Atul Joshi, Uma Mudunuru,
Kathleen M. Buckley, Kelly Robbins,
Celalettin Ustun, Gary W. Reuther,
and Kapil N. Bhalla

PRECLINICAL DEVELOPMENT

- 2243 **Dual Targeting of CDK and
Tropomyosin Receptor Kinase
Families by the Oral Inhibitor
PHA-848125, an Agent
with Broad-Spectrum
Antitumor Efficacy**
Clara Albanese, Rachele Alzani,
Nadia Amboldi, Nilla Avanzi,
Dario Ballinari, Maria Gabriella Brasca,
Claudio Festuccia, Francesco Fiorentini,
Giuseppe Locatelli, Wilma Pastori,
Veronica Patton, Fulvia Roletto,
Francesco Colotta, Arturo Galvani,
Antonella Isacchi, Jurgen Moll,
Enrico Pesenti, Ciro Mercurio,
and Marina Ciomei
- 2255 **Systemic Administration of
Polymeric Nanoparticle-
Encapsulated Curcumin (NanoCurc)
Blocks Tumor Growth and
Metastases in Preclinical Models of
Pancreatic Cancer**
Savita Bisht, Masamichi Mizuma,
Georg Feldmann, Niki A. Ottenhof,
Seung-Mo Hong, Dipankar Pramanik,
Venugopal Chenna, Collins Karikari,
Rajni Sharma, Michael G. Goggins,
Michelle A. Rudek, Rajani Ravi,
Amarnath Maitra, and Anirban Maitra

2265	miR-192/miR-215 Influence 5-Fluorouracil Resistance through Cell Cycle-Mediated Mechanisms Complementary to its Posttranscriptional Thymidilate Synthase Regulation Valentina Boni, Nerea Bitarte, Ion Cristobal, Ruth Zarate, Javier Rodriguez, Evaristo Maiello, Jesus Garcia-Foncillas, and Eva Bandres	2333	Overexpression of GRIM-19 in Cancer Cells Suppresses STAT3-Mediated Signal Transduction and Cancer Growth Takashi Okamoto, Takashi Inozume, Hiroshi Mitsui, Mirei Kanzaki, Kazutoshi Harada, Naotaka Shibagaki, and Shinji Shimada
2276	Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti-Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells Chien-Hsing Chang, Pankaj Gupta, Rosana Michel, Meiyu Loo, Yang Wang, Thomas M. Cardillo, and David M. Goldenberg	2344	Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor David Parry, Timothy Guzi, Frances Shanahan, Nicole Davis, Deepa Prabhavalkar, Derek Wiswell, Wolfgang Seghezzi, Kamil Paruch, Michael P. Dwyer, Ronald Doll, Amin Nomeir, William Windsor, Thierry Fischmann, Yaolin Wang, Martin Oft, Taiying Chen, Paul Kirschmeier, and Emma M. Lees
2287	Tyrosine Phosphatase Inhibitor-3 Sensitizes Melanoma and Colon Cancer to Biotherapeutics and Chemotherapeutics Suman Kundu, Keke Fan, Mingli Cao, Daniel J. Lindner, Ralph Tuthill, Lili Liu, Stanton Gerson, Ernest Borden, and Taolin Yi	2354	Immune Competency of a Hairless Mouse Strain for Improved Preclinical Studies in Genetically Engineered Mice Beverly S. Schaffer, Marcia H. Grayson, Joy M. Wortham, Courtney B. Kubicek, Amanda T. McCleish, Suresh I. Prajapati, Laura D. Nelon, Michelle M. Brady, Inkyung Jung, Tohru Hosoyama, Leslea M. Sarro, Martha A. Hanes, Brian P. Rubin, Joel E. Michalek, Charles B. Clifford, Anthony J. Infante, and Charles Keller
2297	Epidermal Growth Factor Receptor-Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using ⁹⁰Y-Labeled Fully Human Antibody Panitumumab Zhaoefei Liu, Yan Liu, Bing Jia, Huiyun Zhao, Xiaona Jin, Fang Li, Xiaoyuan Chen, and Fan Wang	2365	Expression of ABCG2 (BCRP) Is Regulated by Nrf2 in Cancer Cells That Confers Side Population and Chemoresistance Phenotype Anju Singh, Hailong Wu, Ping Zhang, Christine Happel, Jinfang Ma, and Shyam Biswal
2309	Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression Wioleta Luszczyk, Venugopalan Cheriya, Tarek M. Mekhail, and Ernest C. Borden	2377	Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma Whitney A. Spannuth, Lingegowda S. Mangala, Rebecca L. Stone, Amy R. Carroll, Masato Nishimura, Mian M.K. Shahzad, Sun-Joo Lee, Myrthala Moreno-Smith, Alpa M. Nick, Ren Liu, Nicholas B. Jennings, Yvonne G. Lin, William M. Merritt, Robert L. Coleman, Pablo E. Vivas-Mejia, Yue Zhou, Valery Krasnoperov, Gabriel Lopez-Berestein, Parkash S. Gill, and Anil K. Sood
2322	Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis Nagathihalli S. Nagaraj, J. Joshua Smith, Frank Revetta, M. Kay Washington, and Nipun B. Merchant		

- 2389 | **Suppression of Neurotensin Receptor Type 1 Expression and Function by Histone Deacetylase Inhibitors in Human Colorectal Cancers**
Xiaofu Wang, Lindsey N. Jackson, Sara M. Johnson, Qingding Wang, and B. Mark Evers

- 2423 | **Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer**
Marianne K. Melnik, Craig P. Webb, Patrick J. Richardson, Charles R. Luttenton, Alan D. Campbell, Thomas J. Monroe, Timothy J. O'Rourke, Kathleen J. Yost, Connie M. Szczepanek, Michelle R. Bassett, Kimberly J. Truszkowski, Phyllis Stein, Matthew W. Van Brocklin, Alan T. Davis, Gabriela Bedolla, George F. Vande Woude, and Han-Mo Koo

MOLECULAR MEDICINE IN PRACTICE

- 2399 | **Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth**
Josette Carnahan, Pedro J. Beltran, Carol Babij, Quynh Le, Mark J. Rose, Steven Vonderfecht, Joseph L. Kim, Adrian L. Smith, Karthik Nagapudi, Martin A. Broome, Manory Fernando, Hue Kha, Brian Belmontes, Robert Radinsky, Richard Kendall, and Teresa L. Burgess

- 2430 | **Cisplatin Treatment Induces a Transient Increase in Tumorigenic Potential Associated with High Interleukin-6 Expression in Head and Neck Squamous Cell Carcinoma**
Kim J. Poth, Alexander D. Guminski, Gethin P. Thomas, Paul J. Leo, Ibtissam A. Jabbar, and Nicholas A. Saunders

- 2411 | **Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary**
Seiji Mabuchi, Chiaki Kawase, Deborah A. Altomare, Kenichirou Morishige, Masami Hayashi, Kenjiro Sawada, Kimihiko Ito, Yoshito Terai, Yukihiro Nishio, Andres J. Klein-Szanto, Robert A. Burger, Masahide Ohmichi, Joseph R. Testa, and Tadashi Kimura

LETTERS TO THE EDITOR

- 2440 | **Serine Proteases in Histone Deacetylase Inhibitor-Induced Apoptosis – Letter**
Jürgen Sonnemann, Chithra D. Palani, Lénia Ferrão Beck, James F. Beck, and Bettina Appel
- 2441 | **Serine Proteases in Histone Deacetylase Inhibitor-Induced Apoptosis Still an Unresolved Question – Response**
Maria Piedad Menéndez-Gutierrez, José Antonio Ferragut, Maria del Pilar García-Morales, Miguel Saceda, and Isabel Martinez-Lacaci

ABOUT THE COVER

Genetically-engineered mouse models often represent some of the most physiologically accurate models of cancer from which to understand the tumor microenvironment and with which to perform preclinical trials; however, tumors are often deep-seated and small animal imaging is a requisite for detecting and studying tumor progression. Presented on the cover is an example of multiplex optical and near-infrared imaging of a metastatic childhood rhabdomyosarcoma mouse model showing viable tumor cells in the left lower leg by firefly luciferase luminescence (green channel), pooling of an IR-820 dye due to loss of capillary integrity (red channel), and metal metalloprotease biochemical activity using a biochemically-activated contrast agent (blue channel). For details, see article by Schaffer and colleagues on page 2354.

